In vivo, intratumoral treatment with antibodies against MCAM in melanoma, hepatocarcinoma, osteosarcoma, leiomyosarcoma, and pancreatic tumors reduced tumor growth and the formation of metastases in melanoma and osteosarcoma [21,23]. Here, MCAM is linked to melanoma.